• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Orgenesis Inc.

    7/17/24 10:21:01 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGS alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on July 17, 2024

     

    REGISTRATION NO. 333 -

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    under the

    SECURITIES ACT OF 1933

     

     

     

    ORGENESIS INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Nevada   98-0583166
    (State or Other Jurisdiction   (I.R.S. Employer
    of Incorporation or Organization)   Identification No.)

     

    20271 Goldenrod Lane

    Germantown, MD 20876

    (Address, Including Zip Code, of Principal Executive Offices)

     

    ORGENESIS, INC. 2017 EQUITY INCENTIVE PLAN

    (Full Title of the Plan)

     

    Vered Caplan

    President & Chief Executive Officer

    Orgenesis Inc.

    20271 Goldenrod Lane

    Germantown, MD 20876

    (480) 659-6404

    (Name, Address and Telephone Number, Including

    Area Code, of Agent For Service)

     

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer ☐ Accelerated filer ☐
      Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a) (2) B) of the Securities Act. ☐

     

     

     

     
     

     

    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E of Form S-8, the Registrant hereby makes the following statement: This Registration Statement on Form S-8 is being filed by the Registrant to register an additional 9,000,000 shares of its common stock which, pursuant to an amendment to the Registrant’s 2017 Equity Incentive Plan (the “Plan”), are issuable upon the grant, exercise or vesting of awards under the Plan. These 9,000,000 shares are in addition to the 3,000,000 shares of the Registrant’s common stock which were previously registered pursuant to the Registrant’s Registration Statement on Form S-8 (Commission File No. 333-242195) filed with the Securities and Exchange Commission (the “Commission”) on August 7, 2020 (the “Prior Registration Statement”). Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statement are hereby incorporated by reference.

     

     
     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Exhibit Number   Exhibit Description
    4.1   Articles of Incorporation, as amended (incorporated by reference to an exhibit to our registration statement on Form S-8, filed on August 7, 2020).
    4.2   Amended and Restated Bylaws of the Company, as amended dated December 14, 2022 (incorporated by reference to an exhibit to our current report on Form 8-K, filed on December 19, 2022).
    5.1*   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as to the legality of shares being registered.
    23.1*   Consent of Kesselman & Kesselman.
    23.2*   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).
    24.1*   Power of Attorney (included on the signature page of this Registration Statement).
    99.1   2017 Equity Incentive Plan, as amended (incorporated by reference to an exhibit to our current report on Form 8-K, filed on June 27, 2024).
    99.2   Form of Stock Option Agreement (incorporated by reference to an exhibit to our registration statement on Form S-8, filed on August 7, 2020).
    107*   Calculation of Filing Fee Table.

     

     

    * Filed herewith.

     

    1
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Germantown, Maryland on July 17, 2024.

     

      ORGENESIS INC.
         
      By: /s/ Vered Caplan
        Vered Caplan
        President & Chief Executive Officer

     

    Each person whose signature appears below constitutes and appoints Victor Miller and Evan Fishman, and each of them singly, his/her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him/her and in his/her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Orgenesis Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Vered Caplan   Chief Executive Officer and Director   July 17, 2024
    Vered Caplan   (Principal Executive Officer)    
             
    /s/ Victor Miller   Chief Financial Officer, Treasurer and Secretary   July 17, 2024
    Victor Miller  

    (Principal Financial Officer and Principal Accounting Officer)

       
             
    /s/ Yaron Adler   Director   July 17, 2024
    Yaron Adler        
             
    /s/ Ashish Nanda   Director   July 17, 2024
    Ashish Nanda        
             
    /s/ Itzhak Vider   Director   July 17, 2024
    Itzhak Vider        
             
    /s/ Mark Goodman   Director   July 17, 2024
    Mark Goodman        

     

    2

    Get the next $ORGS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORGS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ORGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Safier Jacob bought $16,883 worth of shares (30,000 units at $0.56) and sold $16,259 worth of shares (30,000 units at $0.54) (SEC Form 4)

    4 - Orgenesis Inc. (0001460602) (Issuer)

    12/4/24 6:48:38 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Safier Jacob bought $3,332 worth of shares (10,100 units at $0.33) (SEC Form 4)

    4 - Orgenesis Inc. (0001460602) (Issuer)

    2/14/24 9:32:21 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Safier Jacob bought $213,280 worth of shares (365,140 units at $0.58) (SEC Form 4)

    4 - Orgenesis Inc. (0001460602) (Issuer)

    2/14/24 9:31:52 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    SEC Filings

    View All

    Orgenesis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Orgenesis Inc. (0001460602) (Filer)

    1/26/26 6:15:30 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Orgenesis Inc. (0001460602) (Filer)

    9/16/25 5:29:47 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Orgenesis Inc. (0001460602) (Filer)

    8/25/25 4:30:43 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Malik Ariel claimed ownership of 1,200,000 shares (SEC Form 3)

    3 - Orgenesis Inc. (0001460602) (Issuer)

    3/18/25 4:06:38 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Vider Itzhak

    4 - Orgenesis Inc. (0001460602) (Issuer)

    12/16/24 2:42:24 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Adler Yaron

    4 - Orgenesis Inc. (0001460602) (Issuer)

    12/16/24 2:42:29 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orgenesis Provides Third Quarter 2024 Business Update

    GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "Orgenesis is making significant progress in redefining accessibility to cell and gene therapies through our decentralized approach. This model is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs. We are dedicated to expanding our clinical initiatives and deepening gl

    11/13/24 8:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Commences Trading on OTCQX® Best Market

    Reports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that its common stock will begin trading on the OTCQX® Best Market under the ticker symbol "ORGS" following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company's failure to meet the required stockholders' equity threshold. Orgenesis plans to attempt to resolve the deficienc

    10/21/24 8:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Announces Reverse Stock Split

    GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company") today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company's existing trading symbol "ORGS". The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq C

    9/23/24 7:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:51:18 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:50:26 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Orgenesis Inc. (Amendment)

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    2/14/24 8:16:04 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    Financials

    Live finance-specific insights

    View All

    Orgenesis Provides Second Quarter 2024 Business Update

    GERMANTOWN, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the second quarter ended June 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "After more than a decade of parallel efforts—on one hand, establishing robust capabilities in cell therapy production by initially serving the industry in a centralized manner and later integrating these capabilities into a decentralized platform, and on the other, forming partnerships through joint ve

    8/8/24 4:05:00 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

    GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners ("Metalmark"), for the acquisition of its approximate 25% stake in Octomera LLC ("Octomera"), the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera's cell processing services, for the three calendar years 2025-2027,

    1/31/24 9:15:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Provides Business Update for Second Quarter of 2023

    Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023. Vered Caplan, CEO of Orgenesis, said, "We are pleased to report revenue of approximately $7.0 million for the second quarter of 2023, which reflects the ongoing rollout of our POCare platform. We recently rebranded the POC Servic

    8/11/23 7:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGS
    Leadership Updates

    Live Leadership Updates

    View All

    Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

    GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure of the advanced therapeutic POCare services and facilities supply business, Octomera. The appointment of Gerhard Bauer as the Vice President of Global Product Implementation at Octomera has been made to enhance the existing process development, regulatory, engineering, equipment, and data/technical service offering and POCare Center hubs. He is also an active contributor to the evolution of the flexible facilities format, Octomera Mobile Process Labs & Units (OMPULs) and network, which allow the

    9/6/23 7:00:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

    GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced the appointment of Elliot Maltz as Chief Financial Officer, effective September 1, 2023. Mr. Maltz succeeds Mr. Neil Reithinger, who is resigning following years of dedicated service and will remain with the Company until he completes his transition of duties, through September 1, 2023. Mr. Maltz brings 16 years of accounting and corporate finance experience working with public and private companies, specializing in the biotechnology, medical devic

    7/13/23 8:30:00 AM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Proactive news headlines including Altamira Gold, AIM ImmunoTech, QC Copper and Gold and Cloud Nine Education

    New York, March 08, 2021 (GLOBE NEWSWIRE) -- - Altamira Gold Corp (CVE:ALTA) (OTCPINK:EQTRF) (FRA:T6UP) reveals four high-grade gold and silver vein structures at its Apiacas project in Brazil click here - Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs click here - QC Copper and Gold Inc (CVE:QCCU) (OTCMKTS:QCCUF) updates on Opemiska drill progress and names new independent director click here - AIM ImmunoTech Inc (NYSEAMERICAN:AIM) doses first healthy subject in intranasal Ampligen coronavirus study click here - Alpine 4 Technologies Inc (OTCQB:ALPP) say

    3/8/21 2:36:14 PM ET
    $TCON
    $ORGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations